Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Pharma and Tech: Jan. 9, 2025

  • Email

Thursday, Jan 9 2025

Who Gets Obesity Drugs Covered by Insurance? In North Carolina, It Helps If You’re on Medicaid

Melba Newsome

GLP-1 agonist medications such as Ozempic accounted for 10% of the North Carolina state employee health plan’s prescription drug spending, so the state is no longer covering them for weight loss alone. Still, it did decide to cover them for Medicaid patients’ weight loss. A look inside the state’s coverage calculus.

How a Duty To Spend Wisely on Worker Benefits Could Loosen PBMs’ Grip on Drug Prices

Arthur Allen

As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the “Big Three” PBMs — or force them to change.

Stimulant Users Are Caught in Fatal ‘Fourth Wave’ of Opioid Epidemic

Lynn Arditi, The Public’s Radio

The migration of fentanyl into illicit stimulants such as cocaine is especially dangerous for people who are not regular opioid users. That’s because they have a low tolerance for opioids, putting them at greater risk of an overdose. They also often don’t take precautions — such as not using alone and carrying the opioid reversal medication naloxone — so they’re unprepared if they overdose.

Syringe Exchange Fears Hobble Fight Against West Virginia HIV Outbreak

Taylor Sisk

Health workers and researchers say an HIV outbreak in West Virginia that three years ago was called “the most concerning” in the U.S. continues to spread after state and local officials restricted syringe service programs.

How Are States Spending Opioid Settlement Cash? We Built a Database of Answers

Aneri Pattani and Lydia Zuraw

From addiction treatment to toy robot ambulances, we uncovered how billions in opioid settlement funds were used by state and local governments in 2022 and 2023. Find out where the money went.

Toxic ‘Forever Chemicals’ Taint Rural California Drinking Water, Far From Known Sources

Hannah Norman

Researchers found toxic “forever chemicals” in drinking water wells dotting California’s rural farming regions, far from known contamination sources. The discovery complicates the state’s drinking water problem, which disproportionately affects farmworkers and communities of color.

Trash Incinerators Disproportionately Harm Black and Hispanic People

Daniel Chang

Across the country, trash incinerators disproportionately overburden majority-Black and -Hispanic communities. Though the number of incinerators has declined nationwide since the 1980s, Florida offers financial incentives to waste management companies that expand existing facilities or build new ones.

Readers Offer ‘Solo Agers’ Support and Reflect on Ancestors

KFF Health News gives readers a chance to comment on a recent batch of stories.

¿Podrían los nuevos medicamentos para bajar de peso estar disponibles para todos?

Melba Newsome

Los medicamentos agonistas GLP-1, conocidos por los nombres comerciales Ozempic, Trulicity y Wegovy, han demostrado ser efectivos para la pérdida de peso y para el manejo de la diabetes tipo 2.

Recent Newsletters

  • The Week in Brief: Friday, May 1, 2026
  • Colorado Checkup: April 29, 2026
  • Rural Dispatch: Tuesday, April 28, 2026
  • The Week in Brief: Friday, April 24, 2026
  • The Week in Brief: Friday, April 17, 2026
  • The Week in Brief: Friday, April 10, 2026
More Newsletters
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF